TFX
HealthcareTeleflex Incorporated · Medical - Instruments & Supplies · $6B
What is Teleflex Incorporated?
Teleflex Incorporated is a global medical device company focused on single-use products for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, it serves hospitals, clinicians, and military channels across dozens of countries.
Teleflex designs, manufactures, and supplies single-use medical devices used in vascular access, interventional cardiology, anesthesia, and surgical procedures. The company generates revenue by selling consumable devices that clinicians rely on for routine and complex procedures — a model that depends on hospital purchasing volumes and procedure rates. Its UroLift System targets a large patient population with benign prostatic hyperplasia, while its Arrow-branded catheter lines serve intensive care and emergency settings worldwide.
Teleflex was founded in 1980 and is headquartered in Wayne, Pennsylvania.
- Arrow-branded vascular access catheters and intraosseous systems
- Interventional cardiology and peripheral vascular devices
- Airway and pain management anesthesia products
- UroLift System for minimally invasive urology treatment
- Ligation clips and fascial closure surgical instruments
Is TFX a Good Stock to Buy?
UQS Score rates TFX as Below Average overall.
Among the five pillars, Valuation stands out as the relative bright spot — the stock appears priced at a level that reflects its current challenges rather than a premium. The Growth pillar lands at Neutral, suggesting the business is not in freefall but is not generating the kind of expansion that would justify a higher composite score.
Quality, Moat, and Risk all register as Weak, pointing to meaningful concerns around business durability, competitive positioning, and financial resilience that investors should weigh carefully.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TFX pay dividends?
Yes — Teleflex Incorporated pays a dividend.
Teleflex pays a regular dividend, which is relatively uncommon among mid-cap medical device companies still investing in product development. The dividend signals a degree of cash generation, though investors should weigh it alongside the Weak Risk and Quality pillar ratings before treating it as a sign of financial strength. Check Teleflex's investor relations page for the current yield and payment schedule.
When does TFX report earnings?
Teleflex reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Quarterly results have reflected the pressures visible in the UQS pillar profile — particularly around quality and growth consistency. Procedure volume trends, hospital capital spending, and UroLift adoption rates are among the factors that tend to drive headline results.
For the most recent quarter's results and guidance, visit Teleflex's official investor relations page.
TFX Price History
-67.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Teleflex Incorporated?
Based on Teleflex Incorporated's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
TFX Long-term Outlook
The Growth pillar at Neutral suggests Teleflex is maintaining its revenue base without strong acceleration. The Weak Risk pillar indicates the path forward carries meaningful uncertainty — whether from competitive pressure, reimbursement dynamics, or balance sheet considerations. A Weak Moat rating means the company may struggle to defend margins if peers intensify competition in catheter or urology markets. The relatively Good Valuation label suggests the market has already priced in a cautious outlook.
Growth drivers
- Continued UroLift System adoption in the large benign prostatic hyperplasia patient population
- Procedure volume recovery in hospital and surgical settings post-disruption
- Geographic expansion of Arrow-branded vascular access products in international markets
Key risks
- Weak competitive moat leaves key product lines exposed to lower-cost or better-differentiated rivals
- Elevated financial risk profile may limit flexibility to invest in new product development
- Reimbursement and hospital procurement pressures could weigh on pricing power
TFX vs Peers
Teleflex competes in the broader medical device and life sciences supply space alongside companies with varying business models and scale.
Avantor focuses on mission-critical materials and consumables for biopharma and lab settings rather than clinical procedure devices.
Bausch + Lomb concentrates on eye health products — surgical, pharmaceutical, and consumer — a narrower therapeutic focus than Teleflex's multi-specialty device portfolio.
Repligen serves bioprocessing workflows for biologics manufacturing, operating upstream of the clinical device market where Teleflex competes.
Frequently Asked Questions
What does Teleflex do?
Teleflex designs and manufactures single-use medical devices for critical care and surgical procedures. Its product lines span vascular access, interventional cardiology, anesthesia, urology, and surgical instruments. The company sells primarily to hospitals, clinicians, and military medical channels around the world.
Does TFX pay dividends?
Yes, Teleflex pays a regular dividend. This is notable for a mid-cap medical device company. However, investors should review the current yield and payout details on Teleflex's investor relations page, and consider the dividend in the context of the company's overall financial risk profile.
When does TFX report earnings?
Teleflex reports financial results on a quarterly basis, as is standard for US-listed companies. For the exact schedule and most recent results, check the investor relations section of Teleflex's official website.
Is TFX a good stock to buy?
UQS Score rates TFX as Below Average. The Valuation pillar is a relative positive, but Quality, Moat, and Risk all score as Weak. Whether TFX fits a portfolio depends on individual risk tolerance and investment goals. The full pillar breakdown is available to UQS Pro members.
Is TFX overvalued?
Based on the UQS Valuation pillar, TFX currently scores as Good — meaning the stock does not appear richly priced relative to its fundamentals. This is one of the few constructive signals in the current UQS profile. Full valuation metrics are available to Pro members.
How does TFX compare to its competitors?
Teleflex operates in a different niche than peers like Avantor, Bausch + Lomb, and Repligen — each of which serves distinct segments of the healthcare and life sciences market. UQS Score provides side-by-side pillar comparisons for Pro members looking to evaluate TFX against sector peers.
What is TFX's market cap bracket?
Teleflex is classified as a mid-cap company. This places it in a segment of the market that can offer growth potential but may carry more volatility and less analyst coverage than large-cap or mega-cap healthcare names.
Who founded Teleflex?
Teleflex's founding history and leadership background are widely documented in public sources, including the company's own investor relations materials and financial filings. The company has operated since 1980 and is headquartered in Wayne, Pennsylvania.
Is TFX a long-term quality investment?
As a long-term quality indicator, the UQS Score currently rates TFX as Below Average. Weak scores across Quality, Moat, and Risk suggest the business faces structural challenges that could affect long-term durability. Investors focused on quality compounders may want to review the full pillar breakdown before committing.
What is the main competitive advantage of Teleflex?
Teleflex's Arrow brand carries recognition in vascular access, and its UroLift System addresses a large underserved patient population. However, the UQS Moat pillar currently rates as Weak, indicating that these advantages may not be sufficient to sustain pricing power or fend off competition over time.
What sector does TFX belong to?
Teleflex operates in the Healthcare sector, specifically within the medical devices and equipment industry. It focuses on single-use consumable devices for hospital and surgical settings, which ties its performance closely to procedure volumes and hospital spending trends.
Unlock Full TFX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics behind each pillar
- ✓Compare TFX side-by-side with sector peers
- ✓Screen for stronger-rated healthcare device alternatives
- ✓Track score changes as new earnings data arrives
Pro Analysis
TFX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 43.3 | 21.1 | 35.0 | 40.2 | 57.1 | 84.6 | +3.7 |
| May 8, 2026 | 39.6 | 14.3 | 35.0 | 40.3 | 39.5 | 88.4 | +0.7 |
| May 7, 2026 | 38.9 | 24.6 | 35.0 | 40.4 | 37.0 | 69.3 | -0.1 |
| May 3, 2026 | 39.0 | 24.6 | 35.0 | 40.4 | 37.0 | 69.8 | +0.6 |
| Apr 26, 2026 | 38.4 | 24.6 | 35.0 | 40.4 | 37.0 | 65.7 | -0.2 |
| Apr 19, 2026 | 38.6 | 24.6 | 35.0 | 40.4 | 37.0 | 67.0 | -0.4 |
| Apr 18, 2026 | 39.0 | 24.6 | 35.0 | 40.4 | 37.0 | 69.6 | -2.6 |
| Apr 16, 2026 | 41.6 | 24.6 | 35.0 | 40.4 | 37.0 | 87.0 | +0.1 |
| Apr 14, 2026 | 41.5 | 24.6 | 35.0 | 40.4 | 37.0 | 86.3 | -4.0 |
| Apr 13, 2026 | 45.5 | 24.7 | 50.0 | 40.4 | 37.0 | 87.8 | +3.8 |
TFX — Pillar Breakdown
Quality
— 20.9/100 (25%)Teleflex Incorporated currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 40.2/100 (20%)Teleflex Incorporated shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 57.1/100 (15%)Teleflex Incorporated maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 83.6/100 (15%)Teleflex Incorporated appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Moat
— 35/100 (25%)Teleflex Incorporated possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TFX.
Score Composition
Financial Data
More Stock Analysis
How is the TFX UQS Score Calculated?
The UQS (Unified Quality Score) for Teleflex Incorporated is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Teleflex Incorporated's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Teleflex Incorporated is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.